StockWatch
·

Arcus Biosciences, Inc. Q3 FY25 Results

RCUSQ3 FY25 Results
Filing
MetricValue ($ M)Q3 FY24
Revenue6.0087.5%
Total Income6.0087.5%
Expenditure148.003.3%
PBT-135.0046.7%
Net Profit-135.0046.7%
OPM
NPM
EPS-1.2727.0%
View full financials

Arcus Biosciences Announces Financial Results for Nine Months Ended Sept 30, 2025

04 May 2026 · 4 May, 8:43 am

Summary

Arcus Biosciences, Inc. issued a press release announcing its financial results for the nine months ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1.

Informational and educational content only. Not investment advice.